RxDoctor Payments DataLook up a doctor →

Venkatachala Mohan, MD

Gastroenterology · Bellevue, WANPI 1194704106

Payments from drug & device makers

$571,362in general payments, 2019–2025

Across 1,563 payments — averaging $365.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$235K
  • Phathom Pharmaceuticals, Inc.$126K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$120K
  • E.r. Squibb & Sons, L.L.C.$61K
  • Takeda Pharmaceuticals U.S.A., Inc.$9K
  • Bristol Myers Squibb$6K
  • plus $16K from 42 others

What the payments were for

  • Consulting fees$11,2882%
  • Speaking & faculty fees$461,89682%
  • Travel & lodging$51,9019%
  • Food & beverage$39,3857%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$571,362 in reported general payments places this provider in the 95th percentile of 447 gastroenterology providers in Washington.

See all gastroenterology providers in Washington

Medicare billing

Part B allowed, 2024
$111,915
Medicare patients
396
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$59,763
LinzessLinaclotide24$20,024
VemlidyTenofovir Alafenamide11$16,114
Mesalamine19$9,240
Dexlansoprazole DrDexlansoprazole17$5,261
DexilantDexlansoprazole24$3,482
Omeprazole174$2,661
Pantoprazole Sodium92$1,380
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl54$841
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl52$799
Famotidine50$577
Lactulose23$454
Sucralfate39$415
Lansoprazole26$408
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl22$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$234,527$79,78643 claims
GileadVemlidy$611$16,11411 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$8,890$3,48224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 447 gastroenterology providers in Washington.

Other gastroenterology in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →